Key result
Mutation of PKD2 phosphorylation sites in a knock-in mouse model significantly reduced agonist-induced dense granule secretion, platelet aggregation, and thrombus formation.
PKD2 is identified as a critical downstream mediator of PKC-induced platelet dense granule secretion and subsequent thrombus formation.
May support PKD2 as an antithrombotic target; leaves open translation to human thrombosis prevention.
Platelets are highly specialized blood cells critically involved in hemostasis and thrombosis. Members of the protein kinase C (PKC) family have established roles in regulating platelet function and thrombosis, but the molecular mechanisms are not clearly understood. In particular, the conventional PKC isoform, PKCα, is a major regulator of platelet granule secretion, but the molecular pathway from PKCα to secretion is not defined. Protein kinase D (PKD) is a family of 3 kinases activated by PKC, which may represent a step in the PKC signaling pathway to secretion. In the present study, we show that PKD2 is the sole PKD member regulated downstream of PKC in platelets, and that the conventional, but not novel, PKC isoforms provide the upstream signal. Platelets from a gene knock-in mouse in which 2 key phosphorylation sites in PKD2 have been mutated (Ser707Ala/Ser711Ala) show a significant reduction in agonist-induced dense granule secretion, but not in α-granule secretion. This deficiency in dense granule release was responsible for a reduced platelet aggregation and a marked reduction in thrombus formation. Our results show that in the molecular pathway to secretion, PKD2 is a key component of the PKC-mediated pathway to platelet activation and thrombus formation through its selective regulation of dense granule secretion.
No takes yet. Share an insight, caveat, or question.
Konopatskaya et al. (2011) studied Thrombosis. PKD2 mutation (Ser707Ala/Ser711Ala) vs. Wild-type (implied) was evaluated on Agonist-induced dense granule secretion, platelet aggregation, and thrombus formation. Mutation of PKD2 phosphorylation sites in a knock-in mouse model significantly reduced agonist-induced dense granule secretion, platelet aggregation, and thrombus formation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: